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Aims Patients with paroxysmal atrial ﬁbrillation (AF) often present with typical angina pectoris and mildly elevated levels of
cardiac troponin (non ST-segment elevation myocardial infarction) during an arrhythmic event. However, in a large
proportion of these patients, signiﬁcant coronary artery disease is excluded by coronary angiography. Here we
explored the potential underlying mechanism of these events.
Methods
and results
A total of 14 pigs were studied using a closed chest, rapid atrial pacing (RAP) model. In ﬁve pigs RAP was performed
for 7 h (600 b.p.m.; n ¼ 5), in ﬁve animals RAP was performed in the presence of angiotensin-II type-1-receptor (AT1-
receptor) inhibitor irbesartan (RAPþIrb), and four pigs were instrumented without intervention (Sham). One-factor
analysis of variance was performed to assess differences between and within the three groups. Simultaneous
measurements of fractional ﬂow reserve (FFR) and coronary ﬂow reserve (CFR) before, during, and after RAP
demonstrated unchanged FFR (P ¼ 0.327), but decreased CFR during RAP (RAP: 67.7+7.2%, sham: 97.2+2.8%,
RAPþIrb: 93.2+3.3; P ¼ 0.0013) indicating abnormal left ventricular (LV) microcirculation. Alterations in microcir-
culatory blood ﬂow were accompanied by elevated ventricular expression of NADPH oxidase subunit Nox2
(P ¼ 0.039), lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1, P ¼ 0.004), and F2-isoprostane levels
(P ¼ 0.008) suggesting RAP-related oxidative stress. Plasma concentrations of cardiac troponin-I (cTn-I) increased
in RAP (RAP: 613.3+125.8 pmol/L vs. sham: 82.5+12.5 pmol/L; P ¼ 0.013), whereas protein levels of eNOS
and LV function remained unchanged. RAPþIrb prevented the increase of Nox2, LOX-1, and F2-isoprostanes, and
abolished the impairment of microvascular blood ﬂow.
Conclusion Rapid atrial pacing induces AT1-receptor-mediated oxidative stress in LV myocardium that is accompanied by
impaired microvascular blood ﬂow and cTn-I release. These ﬁndings provide a plausible mechanism for the frequently
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normal (non-stenotic) coronary arteries.
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Introduction
Angina pectoris is a typical symptom in patients with paroxysmal
atrial ﬁbrillation (AF). In most of these patients, angina pectoris
is associated with mildly elevated cardiac troponin (cTn) levels
suggesting a non-ST-segment elevation myocardial infarction.
However, in a large proportion of these patients, signiﬁcant coron-
ary artery disease can be excluded by coronary angiography
despite clinical symptoms.
1,2
Although the elevated ventricular rate during AF may contribute
to the symptoms of angina pectoris,
1 angina pectoris develops also
in patients with slow ventricular rate and most patients tolerate fast
ventricular rates in sinus rhythm without any clinical symptoms.
3,4
Chronic atrial tachycardia impairs ventricular function by causing
myocardial ischaemia with abnormalities in Ca
2þ handling and con-
tractility. It further leads to alterations in extracellular matrix and
tissue structure and tachycardia-induced cardiomyopathy.
5
Recent reports suggest that myocardial blood ﬂow is reduced,
whereas coronary vascular resistance is elevated in patients with
AF.
6,7 One potential link between AF, abnormal ventricular per-
fusion, and cardiomyocyte dysfunction is the renin–angiotensin
system. Atrial tachycardia or AF increases systemic and cardiac
tissue angiotensin-II (ANG-II) levels.
8,9 ANG-II activates nicotina-
mide adenine dinucleotide phosphate oxidase (NADPH
oxidase)
10–12 and induces oxidative stress
10 that may impair ven-
tricular microvascular blood ﬂow causing myocardial ischaemia,
release of cTn, and ventricular dysfunction. Moreover, repetitive
episodes of AF-induced ventricular ischaemia may contribute to
the development of a pathologic vicious cycle combining AF and
left ventricular (LV) dysfunction.
The present study addressed the molecular basis of the discrete
LV alterations induced by short-term rapid atrial pacing (RAP).
Speciﬁcally, we studied whether RAP increases oxidative stress in
the LV and impairs coronary and microvascular blood ﬂow
through ANG-II-dependent mechanisms.
Methods
Rapid atrial pacing model
A total of 14 pigs (23+3k g )w e r es t u d i e d( Figure 1). Pigs were pre-
medicated, intubated, and instrumented as previously described.
8 Rapid
Figure 1 Study conduct of the in vivo experiments. Sham-operated animals served as control; SR, sinus rhythm.
A. Goette et al. 1412atrialpacingwasperformedinﬁveanimals(PacingGroup;RAP)atarateof
600 b.p.m. (twice diastolic threshold, 2 ms pulse duration) for 7 h. In ﬁve
additionalanimals,RAPwasperformedinthepresenceofirbesartaninfu-
sion (1 mg/kg bolus followed by 0.3 mg/kg/h i.v.; Irbesartan Group;
RAPþIrb), and four pigs were instrumented without further
interventions(sham;Figure1).After7 hofRAP,thechestandthepericar-
dial sac were opened and the heart exposed. Parts of the anterior wall of
the LV were cross-clamped, excised, and immediately frozen in liquid
nitrogen.
Pigs were randomly assigned to the study groups. No animal was
excluded from the study. The experiments were done in a repetitive
orderwitheachshamfollowedbyoneRAPþIrbandoneRAP.Molecular
analyses with regard to protein expression and determination of plasma
levels of cardiac markers were done by investigators blinded to the
invivo results. The animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of Magdeburg.
Measurement of coronary ﬂow reserve
The coronary ﬂow reserve (CFR) measurements were performed
using a pressure temperature sensor-tipped guidewire (Radi Medical
System), which also allows the simultaneous determination of the frac-
tional ﬂow reserve (FFR). The CFR measurements are inﬂuenced by
ﬂow abnormalities in the epicardial arteries and the microcirculation.
In contrast, reduced FFR is speciﬁc to epicardial lesions. Thus, a
normal FFR (non-obstructed epicardial vessels) in the presence of
reduced CFR is indicative of microvascular pathology.
11,12 Angiography
of the left coronary artery was performed using a 6F guiding catheter.
Thereafter, a coronary pressure wire (Radi Medical System) was
advanced into the distal left anterior descending (LAD) artery. Coron-
ary ﬂow reserve was calculated using the Radi Medical System software
package. In brief, the software allows the pressure sensor, located 3 cm
from the tip of the pressure wire, to act also as a distal temperature
sensor, whereas the shaft of the wire acts as a proximal temperature
sensor. Thus, the transit time of an injectant can be calculated.
Three millilitre of saline (room temperature) was injected by hand
into the LAD three times. The mean transit time was recorded after
each injection and then averaged. Thereafter, hyperaemia was
induced by systemic application of adenosine at a dose of 140 mg/kg/
min and the measurements of the transit time were repeated as
described above. The CFR was calculated by the ratio between the base-
line and hyperaemic values. Simultaneously to the CFR, the FFR was cal-
culated by the software. Measurements of FFR and CFR were performed
during normal sinus rhythm before and 15 min after 7 h pacing (Figure 1).
In addition, parameters were also assessed during pacing immediately
before its termination. Baseline FFR value was 0.98+0.08 and CFR
baseline value was 1.6+0.09. Baseline values were used for normaliza-
tion and set to 100%. Baseline values were comparable to previous
reports obtained in pigs (FFR, 0.97+0.03), in which it was shown
that CFR values (mean 2.0+0.9; range 0.7–4.5) are often lower than
2 and show a larger variability compared with humans.
12,13
Western blotting
Extracted LV proteins (30 mg per lane) were separated by 10% PAGE,
followed by transfer to nitrocellulose membranes (Schleicher and
Schuell, Dassel, Germany). Membranes were blocked with Roti-Block
(Roth, Karlsruhe, Germany). The primary antibodies against human
oxidized low-density lipoprotein receptor-1 (LOX-1)/SR-E1 (polyclo-
nal goat IgG, dilution in TBS 1:1000, R&D Systems, Wiesbaden,
Germany), endothelial nitric oxide synthase (eNOS; sc-654 polyclonal
rabbit IgG, dilution in TBS 1:1000, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA), and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, MAB374 mouse monoclonal IgG, 1:1000,
Chemicon Europe, Hamshire, UK) together with the secondary anti-
goat (1:10000, Dianova, Hamburg, Germany), anti-mouse, or anti-
rabbit (1:2000, Cell Signaling Technology, Inc., Danvers, MA, USA)
horseradish-peroxidase-conjugated antibodies, and the SuperSignal
West Dura Extended Duration substrate (Pierce, Rockford, IL, USA)
were used for detection.
For detection of the NADPH oxidase subunits Nox1, Nox2, and
p67phox, proteins were isolated as previously described.
14,15 Mem-
branes were incubated with primary antibodies against Nox1 (Mox1)
(1:1000, Santa Cruz Biotechnology, Inc.), Nox2 (p91phox) (1:1000,
BD Transduction Laboratories, Franklin Lakes, NJ, USA) or p67phox
(1:500, BD Transduction Laboratories) and then with secondary
horseradish peroxidase conjugated anti-rabbit IgG or anti-mouse IgG
(1:2000 or 1:5000; GE Healthcare, Freiburg, Germany). Subsequently,
the same membranes were normalized to GAPDH (1:5000, Abcam,
Cambridge, UK). The protein expression was detected with
Western Lightning Chemiluminescence Reagent Plus (PerkinElmer
Life Sciences, Boston, MA, USA) and quantiﬁed using AIDA Image Ana-
lyzer software (Raytest, Berlin, Germany).
RNA isolation, reverse transcription, and
quantitative PCR
Total RNA was prepared from ventricular tissue by applying the
method of Chomczynski and Sacchi as recently described.
16 One
microgram of total RNA was transcribed into cDNA using AMV
reverse transcriptase (Promega, Mannheim, Germany) as described
previously.
17 The iCycler (BioRad, Munich, Germany) was used for
quantitative PCR. All samples were analysed in triplicate.
Determination of tissue concentrations of
F2-isoprostanes
Frozen LV samples were sliced by scissors and subsequently homogen-
ized by ultraturrax and Dounce homogenizer to yield 10% homogen-
ates in 180 mM KCL, 10 mM EDTA, 0.1 mM BHT, pH 7.4. To
hydrolyse esteriﬁed F2-isoprostanes, the heart homogenates
(100 mL) were treated with 4 M KOH at 408C for 30 min and neutral-
ized by addition of 4 M HCl (pH adjusted to 2.0 with 0.1 M HCl). One
nanogram of 9a,11a-PGF2a-d4 (Cayman Chem. Co., Ann Arbor, MI,
USA) was used as internal standard. The samples were centrifuged
at 5000 g for 15 min and the supernatant was applied onto a C18 car-
tridge. Solid phase extraction and derivatization steps were performed
as previously described.
18 F2-isoprostanes were separated and
measured by gas chromatography negative-ion chemical ionization
mass spectrometry assay (DSQ/Trace GC Ultra, Thermo Fischer
Scientiﬁc, Dreieich, Germany) with ammonia as reagent gas using
selected ion monitoring of the carboxylate anion [M-181] at m/z 569
and m/z 573 for F2-isoprostanes and the deuterated internal standard.
The F2-isoprostane peak co-eluted with authentic 8-iso-PGF2a, but it is
known that other F2-isoprostane isomers occur at the same retention
time.
19 All analyses were performed in triplicate for each tissue sample.
The protein content was determined using the method of Bradford.
20
Determination of plasma concentrations
of NT-pro-BNP and cardiac Tn-I
N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) was measured
on the E-module of the Cobas 6000 analyzer (ROCHE Diagnostics
GmbH, Mannheim, Germany) using the sandwich ECLIA immunoassay
(electrochemiluminescence) for the in vitro quantitative determination
in human serum and plasma. Measuring range varied between
0.6 pmol/L (lower detection limit) and 4130 pmol/L (maximum of the
Irbesartan and ventricular ischaemia 1413master curve). In vitro tests with 51 commonly used pharmaceuticals
showed no interference. Daily quality control was performed using
Elecsys PreciControl Cardiac 1 and 2 (ROCHE Diagnostics GmbH).
Cardiac Tn-I (cTn-I) was measured on the Axsym analyzer (Abbott
Laboratories, Abbott Park, IL, USA) using the three-step MEIA (Micro-
particle enzyme immunoassay) for the in vitro quantitative determi-
nation in serum and plasma. Measuring range varied between 0.02
and 22 ng/mL (linearity). Cross reactivity with muscle Tn-I was
 0.1%, with troponin-T and troponin-C ,1%. Daily quality control
was performed using AxSym Troponin I ADV controls (Abbott Lab-
oratories Ltd., Cootehill, Ireland).
Statistical analysis
The parameters analysed are summarized as mean þ SEM in Table 1.
Haemodynamic parameters are presented as mean values averaged
from repetitive measurements within each animal throughout the
study period. After 7 h pacing, the three groups (sham; RAP;
RAPþIrb) were compared with one-factor analysis of variance
(ANOVA, Table 1). In case of a signiﬁcant global test, the Tukey test
was used for pairwise group comparison (Table 2).
Measurements of FFR and CFR were performed during normal sinus
rhythm before and 15 min after 7 h pacing (end of experiment). To
compare these parameters, differences between ‘baseline’ and this
time point are of special interest. We performed an ANOVA with
‘group’ as main effect and ‘baseline value’ as covariate. In these
models, the group effect gives information for differences between
baseline and the examined time point. All statistical decisions were
made two-tailed with a critical probability of a ¼ 5% without
a-adjustment except the Tukey test for pairwise group comparisons.
Statistical analyses were performed using SAS
w software, version
9.1.3 (SAS Institute Inc., Cary, NC, USA).
Results
Haemodynamic parameters
Haemodynamic parameters were comparable in the three groups
throughout the experiment (Table 1). Mean ventricular rates were
similar at baseline (sham: 90+3 b.p.m.; RAP: 83+7 b.p.m.;
RAPþIrb: 81+7 b.p.m.; P ¼ 0.659), but increased signiﬁcantly in
the two pacing groups compared with baseline (RAP: 134+
9 b.p.m., P ¼ 0.013; RAPþIrb:143+3 b.p.m., P ¼ 0.002) and
sham animals (P ¼ 0.001).
Impact of rapid atrial pacing on NADPH
oxidase subunit expression
Next we tested whether RAP increases the protein levels of LV
NADPH oxidase subunit isoforms (Tables 1 and 2). Although
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
...............................................................................................................................................................................
Table 1 Group comparisons (ANOVA)
Parameter Sham RAP RAP1Irb P-value of ANOVA
Haemodynamic parameters x+sError x+sError x+sError
Right atrial pressure (mmHg) 5.3+0.9 6.2+0.7 5.8+0.9 0.816
Systolic right ventricular pressure (mmHg) 23.7+2.3 26.6+1.4 24.2+2.4 0.576
Pulmonary capillary wedge pressure (mmHg) 6.3+0.3 7.0+0.9 5.8+0.7 0.535
Systolic left ventricular pressure (mmHg) 80+47 4 +47 9 +2 0.375
LV end-diastolic pressure (mmHg) 4.3+0.3 4.6+0.8 5.4+0.7 0.608
Mean heart rate (b.p.m.) 90+38 3 +78 1 +7 0.659
Mean ventricular rate (b.p.m.) 84+3 110+5 114+4 0.003
Molecular markers
Nox1 (OD) 0.140+0.021 0.248+0.064 0.151+0.045 0.246
Nox2 (OD) 0.344+0.049 0.597+0.096 0.326+0.053 0.039
p67phox (OD) 0.380+0.081 0.358+0.034 0.501+0.073 0.305
F2-isoprostane (pg/mg) 303.67+23.48 445.00+36.25 300.00+17.19 0.008
LOX-1 (%) 100.04+28.59 527.10+140.78 65.10+35.86 0.004
eNOS (%) 100.00+36.35 130.04+33.28 98.52+17.39 0.691
eNOS mRNA (%) 100.00+19.99 20.07+8.56 13.02+2.41 0.002
Flow parameters
FFR baseline (%) 100.00+0.00 99.96+2.58 101.36+1.37
7 h 93.40+4.60 96.53+6.64 0.333*
Post 94.27+0.68 96.54+6.18 100.60+3.28 0.327**
CFR baseline (%) 100.00+0.00 100.00+5.97 104.36+10.39
7 h 62.70+3.68 93.28+5.92 0.004*
Post 97.23+2.77 67.73+7.24 93.16+3.29 0.001**
Abbreviations are as explained in the text. OD, optical density.
P-values ,0.05 are marked bold.
*P-value for factor ‘Group’ in ANCOVA to compare RAP vs. RAPþIrb after 7 h pacing with ‘baseline’ as covariable.
**P-value for factor ‘Group’ in ANCOVA to compare the three groups at the end of the experiment with ‘baseline’ as covariable.
A. Goette et al. 1414NOX-1 tended to be up-regulated with RAP (177+26% of sham;
Tables 1 and 2), no between-group differences were detectable
with ANOVA analysis. Nox2 proteins were increased by RAP
compared with sham (173+16% of sham; P ¼ 0.070) and irbesar-
tan prevented the RAP-related Nox2 increase (95+16% of sham;
P ¼ 0.982; Figure 2). Although there was a trend towards increased
protein amounts of p67phox in the RAPþIrb group, the
between-group differences did not reach the level of statistical
signiﬁcance with ANOVA analysis (Figure 2).
Impact of rapid atrial pacing on
expression of LOX-1, eNOS,
and F2-isoprostanes
Besides increasing NADPH subunit abundance, RAP enhanced
thelevelsoftwoadditionalmarkersofoxidativestress,i.e.ventricular
F2-isoprostanes and LOX-1 protein (Tables 1 and 2). F2-isoprostane
concentrations(sham:303.7+23.5 pg/mgprotein)weresigniﬁcantly
higherwithRAP (445+36.3 pg/mg protein; P ¼ 0.02), but remained
stable with irbesartan treatment (300+17.2 pg/mg protein; P ¼
0.996 vs. sham) (Figure 3). Similarly, LOX-1 protein increased by
527.1+140.8% with RAP compared to sham (P ¼ 0.011) (Figure 4).
This increase was prevented by irbesartan (65.1+35.9% of sham;
P ¼ 0.005 vs. sham).
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
T
a
b
l
e
2
G
r
o
u
p
c
o
m
p
a
r
i
s
o
n
s
(
p
o
s
t
-
h
o
c
a
n
a
l
y
s
i
s
w
i
t
h
T
u
k
e
y
t
e
s
t
a
n
d
d
e
r
i
v
e
d
c
o
n
ﬁ
d
e
n
c
e
i
n
t
e
r
v
a
l
s
,
C
I
)
G
r
o
u
p
s
S
h
a
m
–
R
A
P
S
h
a
m
–
R
A
P
1
I
r
b
R
A
P
–
R
A
P
1
I
r
b
P
a
r
a
m
e
t
e
r
D
i
f
f
e
r
e
n
c
e
o
f
m
e
a
n
C
I
P
-
v
a
l
u
e
D
i
f
f
e
r
e
n
c
e
o
f
m
e
a
n
C
I
P
-
v
a
l
u
e
D
i
f
f
e
r
e
n
c
e
o
f
m
e
a
n
C
I
P
-
v
a
l
u
e
M
e
a
n
v
e
n
t
r
i
c
u
l
a
r
r
a
t
e
2
5
.
5
7
.
6
t
o
4
3
.
3
0
.
0
0
7
2
9
.
3
1
1
.
4
t
o
4
7
.
1
0
.
0
0
3
3
.
8
2
1
1
.
6
t
o
1
9
.
2
0
.
7
8
3
N
o
x
2
(
O
D
)
0
.
2
5
2
2
0
.
0
2
1
t
o
0
.
5
2
6
0
.
0
7
0
0
.
0
1
8
2
0
.
2
5
5
t
o
0
.
2
9
1
0
.
9
8
2
0
.
2
7
1
0
.
0
0
3
t
o
0
.
5
4
4
0
.
0
5
2
F
2
-
i
s
o
p
r
o
s
t
a
n
e
(
p
g
/
m
g
)
1
4
1
.
3
2
5
.
3
t
o
2
5
7
.
4
0
.
0
2
0
3
.
7
2
1
1
2
.
4
t
o
1
1
9
.
7
0
.
9
9
6
1
4
5
.
0
3
7
.
6
t
o
2
5
2
.
5
0
.
0
1
2
L
O
X
-
1
(
%
)
4
2
7
.
1
1
0
6
.
6
t
o
7
4
7
.
6
0
.
0
1
1
3
5
.
0
2
2
6
9
.
1
t
o
3
3
9
.
0
0
.
9
4
7
4
6
2
.
0
1
5
8
.
0
t
o
7
6
6
.
0
0
.
0
0
5
e
N
O
S
m
R
N
A
(
%
)
7
9
.
9
3
3
0
.
0
6
t
o
1
2
9
.
8
0
0
.
0
0
4
8
6
.
9
4
3
7
.
1
1
t
o
1
3
6
.
8
5
0
.
0
0
2
7
.
0
5
2
4
2
.
8
2
t
o
5
6
.
9
2
0
.
9
1
8
C
F
R
(
7
h
)
3
4
.
7
8
1
9
.
8
4
t
o
4
9
.
7
1
0
.
0
0
2
C
F
R
(
p
o
s
t
)
2
9
.
5
1
8
.
2
8
t
o
5
0
.
7
3
0
.
0
0
9
4
.
0
7
3
2
1
6
.
2
2
t
o
2
4
.
3
7
1
.
0
0
0
2
5
.
4
3
6
.
7
9
t
o
4
4
.
0
8
0
.
0
2
2
A
b
b
r
e
v
i
a
t
i
o
n
s
a
r
e
a
s
e
x
p
l
a
i
n
e
d
i
n
t
h
e
t
e
x
t
.
O
D
,
o
p
t
i
c
a
l
d
e
n
s
i
t
y
.
P
-
v
a
l
u
e
s
,
0
.
0
5
a
r
e
m
a
r
k
e
d
b
o
l
d
.
Figure 2 Expression of NADPH oxidase subunits in response
to rapid atrial pacing (RAP). Protein expression of NADPH
oxidase subunits Nox1, Nox2, and p67phox was determined in
ventricular myocardium of pigs without RAP (sham), with 7 h
of RAP, or RAP with irbesartan (RAPþIRB). The protein
expression was subsequently normalized on the same gel to
GAPDH as internal control (*P ¼ 0.039, one-factor ANOVA).
Irbesartan and ventricular ischaemia 1415LevelsofeNOSmRNAwerereducedintheRAPgroupto20.1+
8.6% of sham (P ¼ 0.004) without being inﬂuenced signiﬁcantly by
irbesartan treatment (13.0+2.4% of sham; Figure 4 and Table 2).
This indicates ANG-II-independent mechanisms of transcriptional
eNOS regulation during RAP. Nevertheless, protein levels of
eNOS (Table 1) were similar in all groups (P ¼ 0.691; Figure 4).
Coronary ﬂow reserve and fractional ﬂow
reserve measurements
We performed the analyses of CFR and FFR in two steps. First, we
compared the values at the end of the experiment (Figure 1)w i t h
respect to the baseline using all three groups. In the second step, we
compared the values after 7 h pacing between RAP and RAPþIrb.
In these models, the group effect compares differences to baseline.
Fractional ﬂow reserve values (marker for epicardial ﬂow)
measured before, during, and after 7 h RAP (Figure 5A) were com-
parable in all groups (P ¼ 0.327; Table 1). In contrast, CFR (index of
microvascular abnormalities if FFR is normal) differed signiﬁcantly
between the three groups (P ¼ 0.0013, Table 1). Coronary ﬂow
reserve decreased to 62.7+3.7% of baseline during RAP
(Figure 5B) and was at the end signiﬁcantly lower compared with
sham animals (P ¼ 0.009, Table 2). In addition, comparison of
CFR showed signiﬁcant differences between the two pacing
groups after 7 h pacing (P ¼ 0.002, Table 2) as well as to the end
of the experiment (P ¼ 0.022, Table 2). However, CFR was not
different in sham animals compared with RAPþIrb (P ¼ 1.0;
Tables 1 and 2) suggesting involvement of ANG-II-dependent
mechanisms in microvascular abnormalities. The impact of irbesar-
tan therapy in the present pacing model is underlined by the con-
ﬁdence interval of the mean difference in each case of two pacing
groups. Irbesartan therapy reduced signiﬁcantly the decline of CRF
(Figure 5B). The difference of the mean between RAP and RAPþIrb
was 34.78 with a conﬁdence interval from 19.8 to 49.7. At the end
of our experiment, the conﬁdence interval for the difference of the
mean between Sham and RAPþIrb is nearly symmetric to zero
Figure 3 Impact of rapid atrial pacing (RAP) on left ventricular
F2-isoprostane concentrations (P ¼ 0.008, ANOVA). There was a
signiﬁcant increase after 7 h of RAP compared with the sham
group (*P ¼ 0.02; Tukey test). The increment in F2-isoprostane
levels was blunted in the presence of irbesartan (P ¼ 0.996:
sham vs. RAPþIrb; #P ¼ 0.012 RAP vs. RAP-Irb; Tukey test).
Figure 4 Effect of rapid atrial pacing (RAP) on LOX-1 and eNOS expression in the left ventricle. (A) Western blot showing expression of
LOX-1 and eNOS in the three groups. GAPDH was used as internal control. (B) Quantitative analyses of immunoblots shown in (A). Increased
amounts of LOX-1 protein were observed in response to 7 h of RAP (*P ¼ 0.011 vs. sham, Tukey test). The pacing-induced increase of LOX-1
expression is prevented by irbesartan (
#P ¼ 0.005 RAP vs. RAP-Irb, Tukey test). The amounts of eNOS proteins were similar in all groups
(P ¼ 0.691, ANOVA). However, the levels of eNOS mRNA were reduced in response to RAP, independent of RAP being performed in the
absence (RAP vs. sham: *P ¼ 0.004, Tukey test) or presence of irbesartan (RAPþIrb vs. sham: §P ¼ 0.002, Tukey test).
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more pronounced changes in case of high baseline values (P ,
0.05). We found this effect in all calculations for FFR as well as
for CFR.
Plasma concentrations of NT-pro-BNP
and cTn-I
To prove the consequences of increased oxidative stress for ven-
tricular function,
21–24 we measured the plasma concentrations of
NT-Pro-BNP and cTn-I. Plasma concentrations of NT-Pro-BNP
in pigs (n ¼ 10) were 0.786+0.085 pmol/L with no change
during 7 h of RAP or sham operation (0.750+0.053 pmol/L).
There were no signiﬁcant differences in NT-Pro-BNP levels
between the experimental groups. In contrast, plasma levels of
cTn-I increased with RAP from 82.5+12.5 to 613.3+
125.8 pmol/L (n ¼ 3; P ¼ 0.013) and this increase was partly pre-
vented by irbesartan (baseline: 82.3+59.0 vs. 390.0+
90.7 pmol/L after RAP; P ¼ 0.02; n ¼ 3). Sham-operated pigs
showed no change in plasma concentrations of cTn-I (56.7+
29.1 vs. 70.0+50 pmol/L after 7 h).
Discussion
This study shows that acute RAP induces ANG-II-mediated oxi-
dative stress in the LV myocardium that involves NADPH
oxidase activation, increased LOX-1 expression, and elevated F2-
isoprostane concentrations. This is associated with compromised
microvascular blood ﬂow and increased systemic release of
cTn-I. Blockade of AT1-receptors with irbesartan prevents the
maladaptive alterations in the LV suggesting ANG-II signalling as
a major underlying mechanism. Our ﬁndings provide a plausible
mechanism for the frequently observed cTn-I elevation
accompanied with typical angina pectoris symptoms in patients
with paroxysmal AF and normal coronary arteries on angiography.
Atrial ﬁbrillation, oxidative stress,
and microvascular blood ﬂow
Patients without previously documented coronary artery disease
sometimes develop chest discomfort with the onset of AF.
25
Recent studies report that patients with AF have ventricular-ﬂow
abnormalities and higher incidence of cardiac events.
7,26 Consistent
with this notion, coronary artery resistance is markedly elevated
(by 62%), whereas myocardial blood ﬂow is substantially reduced
in AF patients.
7 These ﬁndings are supported by a 67% increase
of the Doppler-derived coronary vascular resistance index
observed in an experimental AF model.
6 Furthermore, vasodilation
in response to exercise is compromised during AF.
27 One potential
link between AF and LV malperfusion is ANG-II. Recent studies
have clearly shown that AF increases systemic ANG-II levels.
8,9
In a previous study using the same experimental approach, we
have demonstrated that 7 h of RAP almost doubles systemic
ANG-II levels.
8 ANG-II activates NADPH oxidase thereby gener-
ating reactive oxygen species (ROS) that can rapidly react with
nitric oxide (NO), leading to peroxynitrite formation, reduced
NO availability, and endothelial dysfunction.
10,28 Major down-
stream effectors of oxidative stress are LOX-1 and F2-isoprostane
(8-iso-prostaglandin F2a)
29,30 with the latter being a speciﬁc and
chemically stable marker of oxidative stress with established invol-
vement in ventricular dilatation and progression to heart
failure.
29,31
Here, we clearly showed that RAP induces ANG-II-dependent
activation of NADPH oxidase (Nox2 subunit) and increases
LOX-1 expression and F2-isoprostane generation. The subsequent
increase in oxidative stress was associated with microvascular ﬂow
disturbances. Speciﬁcally, we observed an up-regulation of Nox2
(gp91phox) protein expression without concomitant changes in
the cytosolic subunit p67phox with RAP. The changes in
NADPH oxidase expression were prevented by blockade of AT1-
receptors with irbesartan. In endothelial cells, ANG-II causes a
rapid (after 7 h) up-regulation of Nox2-protein expression that is
Figure 5 (A) Fractional ﬂow reserve during 7 h of rapid atrial
pacing (RAP) with and without administration of irbesartan.
RAP has no effect on fractional ﬂow reserve compared with
sham animals suggesting that RAP does not affect blood ﬂow in
the epicardial coronary arteries (mean+SEM). (B) Coronary
ﬂow reserve (CFR) in the left anterior descending artery at base-
line (normalized to sham) and after 7 h of RAP. RAP led to a
reduction of CRF compared with sham (*P ¼ 0.009, Tukey
test) and RAPþIrb (#P ¼ 0.022, Tukey test). In contrast, CFR
was comparable in sham and RAPþIrb animals (P ¼ 1.0). A
similar effect could not be observed when RAP was performed
in the presence of irbesartan. Sham-operated animals served as
control.
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12 The Nox2-containing
NADPH oxidase complex has been established in cardiomyocytes
and endothelial cells
32,33 suggesting this complex as a major source
of cardiac ROS generation in response to RAP.
The increase of LOX-1 receptor in the present model and its
prevention by blockade of AT1-receptors resembled the
ANG-II-mediated up-regulation of LOX-1 in human endothelial
cells.
30 The up-regulation of LOX-1 could be a response to
increased oxLDL formation during pacing-induced oxidative
stress. LOX-1 acts as an adhesion molecule in inﬂammatory pro-
cesses
34 and is involved in a variety of cardiovascular diseases
associated with increased ANG-II levels (e.g. heart failure).
35
These ﬁndings indicate LOX-1 as an important mediator in the
ANG-II-related promotion of ventricular oxidative stress induced
by RAP. Taken together, the blockade of AT1-receptors and the
reduction of Nox2, LOX-1, and F2-isoprostane (oxidative stress)
effectively prevent the microvascular ﬂow abnormalities and may
contribute to the effectiveness of AT1-inhibitors to halt the pro-
gression of ventricular remodelling.
In addition to oxidative stress, we show that a relatively brief
episode of AF with a moderate increase in ventricular response
may enhance the systemic cTn-I levels demonstrating discrete
cardiac ischaemia. This can be explained by the induction of oxi-
dative stress-induced microvascular ﬂow abnormalities in the LV.
Accordingly, we detected reduced CFR in the presence of stable
FFR. Most importantly, the CFR abnormalities remained present
for at least 15 min after termination of RAP. Reduced NO avail-
ability in the coronary circulation is one potential mechanism to
explain the CFR abnormalities. Besides consequences for the vas-
cular tree, NO deﬁciency increases chamber stiffness and impairs
diastolic performance, which may contribute to reduced circula-
tion in the microvasculature. In the present study, we demonstrate
stable amounts of eNOS protein in the LV excluding signiﬁcant
down-regulation of eNOS within 7 h of RAP. However, eNOS
mRNA levels strongly declined with RAP, by 80%, suggesting
that reduced eNOS proteins may play a role if AF episodes
persist for longer periods of time. Since eNOS activity was not
determined in the present study, we cannot exclude the possibility
that reduced eNOS activity contributes to the abnormalities in this
setting.
ARBs and microvascular blood ﬂow
ANG-II has been reported to be abundant in ﬁbrillating atria
36 and
AF is associated with a down-regulation of atrial AT1-receptor and
an up-regulation of AT2-receptor proteins.
37 Cardiac AT2-receptor
expression is upregulated during myocardial ischaemia and in con-
trast to AT1-receptor activation, the AT2-receptor promotes
NO-dependent vasodilatation and inhibits growth and remodelling
processes.
38 At the molecular level, ANG-II-receptor blockers
(ARBs) have been shown to increase NO availability and it is poss-
ible that this effect is mediated by a stronger ANG-II-dependent
activation of AT2-receptors. ARBs also attenuate aortic intimal
proliferation and markedly decrease the enhanced LOX-1
expression in the aorta of hypercholesterolemic animals.
39 Irbesar-
tan reduces the formation of vascular superoxide (O2
2)i nar a t
model of congestive heart failure.
40 Here we show that oxidative
stress and microvascular ﬂow abnormalities occur immediately
after new-onset AF likely representing key initiator mechanisms
of AF-related ventricular remodelling. Of note, ARB therapy
could attenuate most of the functional and molecular changes in
the LV during RAP. However, further clinical studies will be
needed to validate the present ﬁndings and to determine
whether ARB therapy can also reduce ANG-II-dependent ventri-
cular abnormalities if they are already established.
Atrial ﬁbrillation and left ventricular
dysfunction
Atrial ﬁbrillation is known to be associated with an increased risk
of LV dysfunction, especially in patients with ischaemic cardiomyo-
pathy.
41,42 Here we show that brief episodes of AF do not signiﬁ-
cantly change ventricular function because systemic levels of
NT-Pro-BNP and diastolic LV pressures are unchanged. Neverthe-
less, it is quite possible that repetitive episodes of AF might cause
ventricular dysfunction providing a plausible explanation for the
higher incidence of heart failure deteriorations with increasing
number of AF recurrences.
4,5,41,42
Clinical implications
To the best of our knowledge, the present study is the ﬁrst to
provide a potential underlying mechanism for the typical cTn-I
elevation accompanying the angina pectoris symptoms in patients
with paroxysmal AF and normal (non-stenotic) coronary arteries.
With RAP, we showed oxidative stress and microvascular ﬂow dis-
turbances that are consistent with previous reports showing that
AF can induce ischaemic ST-segment depression in the surface
ECG of patients with normal coronary arteries.
43 Importantly,
we can show that treatment with ARBs prevents both the molecu-
lar basis of oxidative stress and the related ventricular ischaemia
induced by RAP. Thus, ARB therapy may be an effective thera-
peutic option for this clinical situation.
Several studies have identiﬁed AF as an independent risk factor
for cardiovascular events and death, especially in patients with
ischaemic heart disease.
44,45 The present study suggests that AF
can aggravate ventricular ischaemia, which might further compro-
mise ventricular function potentially explaining the worse
outcome of heart failure patients developing AF. Our results also
support recent ﬁndings that asymptomatic (occult) coronary
artery disease might become manifest during an episode of AF.
Of note, the actual ventricular rate accompanying AF is not
related to the ischaemic ventricular changes on the surface ECG
suggesting that an AF-related, but ventricular rate-independent,
mechanism induces myocardial perfusion abnormalities.
46 This
notion is supported by the moderate increase in ventricular
rates during RAP we observed.
Atrial tachyarrhythmias and AF are recognized risk factors for
the increased mortality of patients with acute myocardial infarc-
tion,
47,48 and large myocardial infarctions frequently promote the
development of AF.
49 Conversely, our study suggests that AF per
se may increase infarct expansion by impairing microcirculation.
Thus, future studies are warranted to determine whether immedi-
ate antiarrhythmic interventions in patients with myocardial infarc-
tion and new-onset AF may improve patient’s prognosis.
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The present study has several limitations. The number of included
animals was limited. However, the observed functional changes
have consistent molecular correlates at several components of
the cellular signal transduction suggesting validity of our ﬁndings.
We did not measure activity of NADPH oxidase, but the protein
level of Nox2 (gp91phox) highly correlates with enzymatic activity
of NADPH oxidase.
11 Nevertheless, we cannot exclude that
additional signiﬁcant differences between the groups exist and con-
tribute to the clinical phenotype.
We have not studied all potential mechanisms, which may inﬂu-
ence microvascular ﬂow during RAP. Activation of inﬂammatory
pathways, endothelial damage, increased catecholamine levels,
and/or enhanced activation of the sympathetic nervous system
may also produce ventricular ﬂow abnormalities. In addition, the
impact of chronic persistent AF on LV perfusion has to be estab-
lished. However, patients with persistent or permanent AF rarely
present with acute angina pectoris symptoms, whereas the latter
are characteristic for patients with paroxysmal AF.
1 Finally, we
did not assess the effects of repetitive episodes of RAP on LV func-
tion. Thus, further studies are needed to determine the additive
effects of repetitive AF episodes on LV perfusion and performance.
Conclusions
The data obtained from these acute pacing experiments clearly
demonstrate that RAP induces ANG-II-dependent NADPH
oxidase-mediated oxidative stress in the LV myocardium, which
may contribute to the impaired microvascular blood ﬂow and
increased cTn-I release. These ﬁndings provide a plausible under-
lying mechanism for the occurrence of acute chest pain and
cTn-I releases in patients with paroxysmal AF and normal (non-
stenotic) coronary arteries.
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